



JOURNAL OF BIOMEDICINE AND TRANSLATIONAL RESEARCH

Copyright©2015 by Faculty of Medicine Diponegoro University and Indonesian Doctor Association, Central Java Region

The Expression of TTF-1 and CK-7 in the Diagnosis of Pleural Effusion Cytology Suspected Lung Adenocarcinoma

Patricia Diana Prasetyo, IkaPawitra, IndraWijaya

Department of Pathological Anatomy Faculty of Medicine Diponegoro University Semarang.

Article info

History :

Received 4 March 2015

Accepted 28 Augsts 2015

Available 1 September 2015

ABSTRACT

Background: Lung cancer is the major cause of death worldwide including Indonesia especially nonsmall cell lung cancer (NSCLC) group including adenocarcinoma, squamous carcinoma (SqCCA) and large cell lung cancer (LCLC). Incidence of lung adenocarcinoma continues to rise up about 40% of all NSCLC in January 2012-Desember 2013; and 15% of pleural effusion associated with malignancies. To confirm the diagnosis, monoclonal antibody anti -TTF-1 and CK-7 are currently used to identify types of lung tumors adenocarcinoma , especially when cytomorfologically is doubtful.

Methods: The design of the study was descriptive observational, that included individuals who were hospitalized at Dr. Kariadi Teaching Hospital in Semarang, confirmed by thorax X-ray with diagnosis of suspected lung malignancy, between January 2012 – 2013. The expression of TTF-1 and CK-7 Were analysed using immunohistochemistry.

Result: A total of 20 samples subjected to Pearson correlation test with result of p value = < 0,001 and r = 0,867. The highest expression TTF-1 in the all study sample was adenocarcinoma (73.3%) and highest expression CK-7 was also adenocarcinoma (68.6%).

Conclusion: The expression of TTF-1 and CK-7 on tissue samples can be used to confirm adenocarcinoma malignancy on the cytological sample of suspected malignant pleural effusion

Keywords: TT-1, CK-7, adenocarcinoma, pleural effusion, nonsmall cell lung cancer (NSCLC)

INTRODUCTION

Lung cancer is a major cause of death in the world, including Indonesia, especially non-small cell lung cancer (NSCLC) including adenocarcinoma, squamous carcinoma (SqCCA) and large cell lung cancer (LCLC) that occurs in about 80% of all lung cancer.^{1,2} Recently, the incidence rate of lung adenocarcinoma is increasing about 40% of all non-small cell lung cancer (NSCLC).³ Lung cancer in Indonesia was ranked fourth of all cancers, Data from Ministry of Health shows the number of cancer cases in Indonesia reached to 6% of the population.^{4,5}

Pleura effusion is a condition where there is an excessive fluid in the pleural cavity, 15% of the cases are associated with malignancy proven by the presence of malignant cells in cytological examination from pleural effusion or biopsy of the lung. This malignancy could be categorized into adenocarcinoma, squamous cell carcinoma, small cell carcinoma, mesothelioma malignancy, neuroendocrine tumor.^{6,7} The expressions of TTF-1 and CK-7 antibodies are used to differentiate between adenocarcinoma with other carcinoma. TTF-1 and CK-7 are available in the market and relatively inexpensive. Yue-Chiu Su (2006) showed that TTF-1

antibody and CK-7 can differentiate adenocarcinoma lung primer and metastatic. TTF-1 is a sensitive marker for pulmonary and thyroid adenocarcinoma. TTF-1 immunohistochemistry is a very sensitive and highly specific method in the differential diagnosis of primary and metastatic lung adenocarcinomas and should be used in the everyday clinical practice.^{8,9,10}

The examination by immunocytochemistry staining for Thyroid transcription factor-1 (TTF-1), Cytokeratin 7 (CK 7), Cytokeratin 20 (CK 20), are important to differentiate among those type of cancers (Kingshuk R et al, 2013)^{8,9}.

This study using a cytology block of pleural effusion. To diagnose malignant cells in the cytology preparations sometimes difficult to distinguish between the benign and malignant cells, lead to misdiagnosis. Therefore, the usage of TTF-1 and CK-7 antibodies to identify types of lung adenocarcinoma is very useful to determine whether the cells are malignant or not. This research using TTF-1 and CK-7 monoclonal antibody to differentiate specifically between adenocarcinoma with other carcinoma, without increasing cost of examination.

METHODS

This study was a cross sectional design. This study population included individuals admitted to the Dr. Kariadi Teaching Hospital in Semarang that had been thorax X-ray with diagnosis of suspected malignant pleural effusion. Cytological examination of Pleural effusion performed using immunohistochemistry method. The number of research sample were consecutive population who met the inclusion criteria. The Expression of TTF-1 positive was brown staining at the nuclei where as CK7 positive was brown staining in the cytoplasm, the color intensity and percentage are calculated using Allred Score⁸. All met inclusion criteria patients had to sign an informed consent form to approve their participation, and the research proposal have been approved by The Ethical Review Board of the Institution.

RESULT AND DISCUSSION

A total of 20 samples with suspected malignant pleural effusion met the inclusion criteria were included in this study.

Table 1. Descriptive Diagnosis of TTF-1 and CK-7 in 20 patients.

Diagnosis	n	Mean	SD	Median	Min	Max
TTF-1						
Suspected Adenocarcinoma	11	5.55	1.036	6.00	4	7
Suspected Adenosquamous cell carcinoma	3	2.67	0.577	3.00	2	3
Suspected Squamous cell carcinoma	6	1.33	1.506	1.00	0	3
CK-7						
Suspected Adenocarcinoma	11	6.00	1.096	6.00	4	8
Suspected Adenosquamous cell carcinoma	3	4.67	2.082	4.00	3	7
Suspected Squamous cell carcinoma	6	1.50	1.761	1.00	0	4

Table 1 shows the expression of TTF-1 maximum value on sample of suspected adenocarcinoma with score 7, while minimum value on sample of suspected squamous cell carcinoma with score 0. Whereas CK-7 shows maximum value on sample of suspected adenocarcinoma with score 8, while minimum value on squamous cell carcinoma with score 0.

Table 2. Pearson Correlation Test Result

Variable	Mean ± SD	R	P
TTF-1	3.85 ± 2.254	0.867	< 0.001*
CK-7	4.45 ± 2.460		

Table 2. shows Pearson correlation p value = < 0.001 and r = 0.867, so we conclude that there is a significant relationship between expressions of TTF-1 to CK-7 with very strong power of positive relationship

Table 3. Percentage TTF-1 and CK-7

Diagnosis	TTF-1				p
	Positive		Negative		
	n	%	n	%	
Suspected Adenocarcinoma	11	73.3	0	0	0.009
Suspected Adenosquamous cell carcinoma	2	14.4	1	20	
Suspected Squamous cell carcinoma	2	12.3	4	80	
Diagnosis	CK-7				P
	Positive		Negative		
	n	%	n	%	
Suspected Adenocarcinoma	11	68.8	0	0	0.003
Suspected Adenosquamous cell carcinoma	3	18.8	0	0	
Suspected Squamous cell carcinoma	2	12.5	4	100	

On Table 3, result of percentage expression of TTF-1 in all sample was highest on suspected positive adenocarcinoma was 73.3% and lowest was on sample of suspected squamus cell carcinoma of 12.3%. While percentage of expression of CK-7 in all sample was highest on suspected positive adenocarcinoma of 68.8 % and lowest on sample of suspected squamus cell carcinoma of 12.5 %.





Figure 1. The expression of TTF-1 and CK-7 in all patients (in percentage).

The graphs show the expression of TTF-1 and CK-7 are dominant in patients with suspected lung adenocarcinoma, meanwhile less expressed in patients suspected lung squamous cell carcinoma.



A. Magnification 100X, Haematoxylin Eosin, shows group of cancer cell (arrow)

B. Magnification 200X, Papanicolaou stain, shows group of cancer cell (arrow)

Figure 2. Malignant cell in Haematoxylin Eosin and Papanicolaou stained






Figure 3. Malignant cell stained TTF-1 positive, brown staining on the core of malignant cell (arrow)



A. Magnification 100X, CK-7 staining

B. Magnification 400X, CK-7 staining



C. Magnification 100X, CK-7 staining

D. Magnification 400X, CK-7 staining

Figure 4. Microscopic staining of CK-7 Positive, arrow showed cell stained CK-7 positive, brown staining on the cytoplasm of malignant cell (arrow)

Lung cancer is the leading cause of death worldwide. WHO classification of 2004, there are seven main histological types of lung tumors epithelial malignancy and over 20 variants. Lung epithelial tumor of non-small cell lung carcinoma, includes: adenocarcinoma, squamous cell carcinoma, large cell and large cell undifferentiated carcinoma.¹³ Several studies have shown a tendency of adenocarcinoma type to metastasize faster, and its incidence continues to increase. Adenocarcinoma are found mainly in Asian women (72% of cancer cases in Japan, 65% in Korea, 61% in China Singapore). The differences in

histological types are mostly affected by variations of smoking habits, while in United States the incidence of adenocarcinoma of the lung is 38% of all lung cancers.^{11,12,13}

Table 3 shows the expression of TTF-1 in the sample suspected adenocarcinoma was 73.3% in the sample suspected squamous cell carcinoma was 13.3%, whereas, the expression of CK-7 suspected adenocarcinoma showed 68.8% and in the sample of squamous cell carcinoma was 12.5%. the results indicate that the expression of TTF-1 and CK-7 are more dominant on suspected adenocarcinoma than the other. This result is almost the same with the previous study on the expression of TTF-1 and CK-7, by Yue-Chiu Su (2006), They found that TTF-1 antibody and CK-7 can be used to differentiate adenocarcinoma lung primer and metastatic.^{14,15}

Primary lung malignancy contain Surfactant protein A (SPA) which is a major component of surfactant and Clara cell, which is synthesized and excreted in the lung alveoli by type II pneumocyte. In pleural effusion caused by primary lung malignancy, it contains high concentration of Surfactant protein A (SPA) especially in lung adenocarcinoma, that then will express TTF-1. Evidences indicated that TTF-1 is very important in the development of lung embryogenesis and increased expression in Clara cells and type II pneumocyte.^{15,16}

In this study, the expression of TTF-1 in adenocarcinoma was 73.3%, adenosquamous 14.4%, while the squamous cell carcinoma contain a little Surfactant protein A (SPA) so that in this study the expression is only 12.2%. According to the previous studies, TTF-1 expressing specific tissue indicating the specific molecular biomarkers in primary tumors of lung adenocarcinoma.¹³

In the group of CK-7 the most dominant expression was in the samples of suspected lung adenocarcinoma by 68.8%. Cytokeratin-7 (CK7) is a human protein that encodes the gene KRT7, a type II keratin. Cytokeratin 7 is a protein that mainly located in the lung and breast organs. In research conducted by Peiguo Chu stated that the expression of CK-7 in lung adenocarcinoma was 100% while the squamous cell carcinoma of lung was 0% in all cases.¹⁶ Although CK-7 is able to identify lung adenocarcinoma, but it can also be positive in the metastasis of other tumors. CK-7 and CK-20 are often combined, especially when suspected of metastases from colorectal tumors (intestinal tumors), in metastatic colorectal tumors in the lung CK-7 is negative while CK-20 is positive, therefore clinical examination is very important to predict the primary or secondary tumor.^{16,17}

The use of antibody TTF-1 and CK-7 to identify types of lung tumors adenocarcinoma can be used to confirm a doubtful cytomorphological that can

differentiate between malignant or not.¹⁸ From the discussion above we can conclude that the expression of TTF-1 and CK-7 protein are overexpressed in samples of lung adenocarcinoma.^{19,20}

CONCLUSION

TTF-1 and CK-7 expressions can be used to detect malignancy especially lung adenocarcinoma using cytology preparation. The expression of TTF-1 and CK-7 is very strong positive predictor ($p \leq 0.001$ and $r = 0.867$) and biomarker for lung adenocarcinoma

SUGGESTION

Using other specific antibody immune histochemistry as the marker of lung adenocarcinoma is recommended to avoid secondary tumor

ACKNOWLEDGMENTS

We thank dr. Dik Puspasari, Pathologists, and Udadi Sadhana, Pathologist who participating in this research. Appreciated also to Mr. Arifin and Mrs. Wiwik for the help in laboratory works.

REFERENCES

1. Apdani R, Karakteristik Penderita Kanker Paru Yang Dirawat Inap Di Bangsal Paru Rumah Sakit Umum Dr. Soedarso Pontianak Periode 1 Januari 2006 - 31 Desember 2010. Skripsi. Pontianak: Program Studi Pendidikan Dokter Fakultas Kedokteran Dan Ilmu Kesehatan Universitas Tanjungpura, 2011.
2. Diederich S. Focus On: Lung Cancer. In CT screening for lung cancer. Cancer Imaging.; 8:24-26. 2008
3. Fatima N, Cohen C, Lawson D.M.T, Siddiqui M.T. TTF-1 and Napsin A Double Stain. Cancer Cytopathology; 25:127-32.2011
4. Flieder D.B. Screen-Detected Adenocarcinoma of the Lung. In Practical Points for Surgical Pathologists Am J Clin Pathol; 119(1):39-57, 2003
5. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incident and mortality in Europe in 2006. Ann Oncol; 18:581-92., 2007
6. Hecht J. L, Pinkus, J.L, Weinstein L.J, Pinkus G.S. The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin. Am J Clin Pathol; 116:483-488, 2001

7. John C, Ruckdeschel, *Myths & Facts* about lung cancer: What you need to know. USA. Bryson Biomedical. 2006
8. Kingshuk Roy Choudhury, Kevin J. Yagle, Paul E. Swanson, Kenneth A. Krohn, Joseph G. Rajendran. A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images. *Journal of Histochemistry & Cytochemistry*. Volume 58(2): 95, 2010
9. Kanker Paru. dalam *Pedoman Diagnosis & Penatalaksanaan Di Indonesia*. : Perhimpunan Dokter Paru Indonesia. 2013
10. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Xuemin Gu, et al. A five-gene and corresponding-protein signature for stage-II lung adenocarcinoma prognosis. *Clin Cancer Res*. 2010.
11. Lam B, Lam W.K, Lam C.L, Ooi G.C, Ho JCM, Wong M.P. et al. Adenocarcinoma of the lung in Chinese patients: a revisit and some perspectives from the literature. *Postgrad Med J* 2001;77:708-12
12. Lung Cancer, Lung Adenocarcinoma, College of American Pathologists, Dec.. Available www.cancer.gov, 2006
13. Lin C.C, Chen L.C, Tseng V.S, Yan J.J, Lai W.W, Su W.P. Malignant pleural effusion cells show aberrant glucose metabolism gene expression Division of Hematology/ Oncology Department of Internal Medicine Hospital and College of medicine, National Cheng Kung University College. Taiwan. 2010
14. Mignotte H.N, Guillem P, Vesin A, Toffart A.C, Colonna M, Bonnetterre V, et al. Primary lung adenocarcinoma: characteristics by smoking habit and sex. *Eur Respir J*; 38: 1412-1419, 2011.
15. *Persatuan Ahli Penyakit Dalam*. Buku Ajar Ilmu Penyakit Dalam jilid 2. Jakarta : Balai Penerbit FK UI; VII:915-18, 1996
16. Parkin M, Tyczynski J.E, Boffetta P, Samet J, Shields P, Caporaso N, Lung cancer epidemiology and etiology. In . Travis W.D, Brambilla E, Hermelink H.K.M, Harris C.c, Editors. *Tumours of the Lung, Pleura, Thymus and Heart*. World Health Organization Classification of Tumours. 2004.
17. Pao W, Vincent A, Miller, Katerina A. Politi, Gregory J, et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. *PLoS Medicine*.;2(3):225-33, 2005
18. Rimmelman M. *New Lung Adenocarcinoma Classification In Daily Practice*. 2012.
19. Syahrudin E, Pratama AD, Arief N. A retrospective study : clinical and diagnostic characteristics in advanced stage of lung cancer patients with pleural effusion in persahabatan hospital 2004 – 2007. *J Respir Indo*;30:146-151, 2010
20. William D. Travis, Brambilla E; Noguchi M, Andrew G, Nicholson. Diagnosis of Lung Cancer in Small Biopsies and Cytology. In *Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/ European Respiratory Society Classification*. *Arch Pathol Lab Med*.;137:668-684, 2013